



FORM PTO 1449 (modified)

ATTY DOCKET NO.  
040388/0110SERIAL NO.  
08/986,668U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEAPPLICANT  
Jean-Francois BACH et al.LIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)FILING DATE  
December 5, 1997

GROUP

1644

Date Submitted to PTO: April 3, 1998

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

R	A1	Hirsch et al., "Anti-CD3 F(ab') <sub>2</sub> Fragments are Immunosuppressive in Vivo Without Evoking Either the Strong Humoral Response or Morbidity Associated with Whole mAb" <u>Transplantation</u> 48:1117-1123 (1990)
	A2	Hirsch et al., "Differential T Cell Hyporesponsiveness Induced by In Vivo Administration of Intact or F(ab') <sub>2</sub> Fragments of Anti-CD3 Monoclonal Antibody" <u>The Journal of Immunology</u> 147:2088-2093 (1991)
	A3	Herold et al., "Prevention of Autoimmune Diabetes with Nonactivating Anti-CD3 Monoclonal Antibody" <u>Diabetes</u> 41:385-391 (1992)
	A4	Hughes et al., "Induction of Helper Cell Hyporesponsiveness in an Experimental Model of Autoimmunity by Using Nonmitogenic Anti-CD3 Monoclonal Antibody" <u>J. Immunol.</u> 153(7):3319-3325 (1994)
	A5	Chatenoud et al., "Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice" <u>Proc. Natl. Acad. Sci. USA</u> 91:123:127 (1994)
	A6	Johnson et al., "Use of Anti-CD3ε F(ab') <sub>2</sub> Fragments In Vivo to Modulate Graft-Versus-Host Disease Without Loss of Graft-Versus-Leukemia Reactivity After MHC-Matched Bone Marrow Transplantation," <u>The A. Assoc. Immuno.</u> pp. 5542-5554 (1995) <u>J. Immunol.</u> 154(10):5542-5554 (1995)

EXAMINER

DATE CONSIDERED

6/22/98

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.